What Price Is Right for Genzyme?
The chief executive of Genzyme, Henri A. Termeer, on Tuesday appeared to soften his tone about a possible sale, a day after his company rejected a $69-a-share offer from Sanofi-Aventis. In an interview with The Boston Globe, Mr. Termeer acknoweldged that Genzyme was now in play even as he reiterated that Sanofi’s price undervalued the [...]
